St. Joseph’s Health is now offering Pluvicto for certain patients with advanced prostate cancer at St. Joseph’s University ...

A new study suggests a protective vest tested on a manikin during NASA's first Artemis moonshot could slash the radiation ...

Haswitha Sabbineni has an idea that could lead to a targeted treatment for prostate cancer. To obtain the rare isotope she ...

UPMC welcomes Brett Lewis, M.D., medical director and radiation oncologist, to the UPMC Hillman Cancer Center team in ...

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

Three decades after UC San Francisco pioneered "active surveillance" for patients with low-risk prostate cancer, a new study has found that the vast majority of veterans with the diagnosis pursued ...

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.

Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local ...

New research has exposed significant differences in access to cancer treatment across Aotearoa, with some rural patients — including Māori — less likely to receive radiotherapy than people living in ...

Former President Joe Biden's cancer has spread to his bones, according to his son Hunter. NPR's A Martinez asks Johns Hopkins Professor Otis Brawley about prostate cancer diagnoses and treatments.

Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial ...